

FORM PTO-1449 US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. 014835.77.02-034	SERIAL NO. 10/527,904
LIST OF DOCUMENTS CITED BY APPLICANT		APPLICANT Redfield, et al.	
		FILING DATE 07-07-2005	GROUP 1617

U.S. PATENT DOCUMENTS

EXAMINE R INITIAL	PATENT or APPLICATION NUMBER	ISSUE OR PUBLICATION DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/K.C./	6096780	08-01-2000	Shiraishi et al.			
/K.C./	6,013,644	1/11/2000	Mills, et al.			
/K.C./	5,962,462	10/5/1999	Mills, et al.			
/K.C./	6,150,530	11/21/2000	Kempf, et al.			
/K.C./	5,994,136	11/30/1999	Naldini			
/K.C./	20030099944	5/29/2003	Schaffer et al.			
/K.C./	20030060457	3/27/2003	Schaffer et al.			

	DOCUMENT NUMBER	PUBLICATION DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
/K.C./	WO 99/48504	09-30-1999	Lisziwicz, at al.				
/K.C./	WO 99/47146	09-23-1999	Lisziwicz, at al.				
/K.C./	WO 02/053096	11 July 2002	Schaffer				
/K.C./	WO 02/062123	15 August 2002	Anderson				
/K.C./	WO98/25604	12/12/1997	Merck				
/K.C./	WO00/51610	3/1/2000	Merck				
/K.C./	WO02100401	6/5/2002	Schering				
/K.C./	WO03/027671	9/25/2002	Eirx				

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

/K.C./	ANDRIEU, et al. "Results of a 2-year exploratory study with cyclosporin a in human immunodeficiency virus infection." (1998) in <i>Autoimmune Aspects of HIV Infection</i> , eds. (R. Soc. Med. Services, London), pp. 191-194.
/K.C./	Paton, et al., "Hydroxychloroquine, hydroxycarbamide and didanosine as economic treatment for HIV-1" <i>The Lancet</i> , (2002) V.359, 1667
/K.C./	Spada, et al. "An Evaluation of Antiretroviral Therapy Associated with α -Tocopherol" <i>Clin. Chem., Lab. Med</i> (2002) 40(5), 456-459.
/K.C./	Calabrese, L., Lederman, M., Spritzler, J., Coombs, R., Fox, L., Schock, B., Yen-Lieberman, B., Johnson, R., Mildvan, D. & Parekh, N. (2002) <i>J. Acquired Immune Defic. Syndr.</i> 29, 356-362.
/K.C./	Lori, et al. "Strucutured treatment interruptions as a potential alternative therapeutic regimen", <i>Journal of Antimicrobial Chemotherapy</i> (2002) 50, 155-160.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO. 014835.77.02-034	SERIAL NO. 10/527,904
LIST OF DOCUMENTS CITED BY APPLICANT			APPLICANT Redfield, et al.	
			FILING DATE 07-07-2005	GROUP 1617
/K.C./		Bjornal, A., Sonnerborg, A., Tscherning, C., Albert, J. & Fenyo, E. (1999) <i>AIDS Res. Hum. Retroviruses</i> 15, 647-653.		
/K.C./		Loetscher, P., Seitz, M., Baggiolini, M. & Moser, B. (1996) <i>J. Exp. Med.</i> 184, 569-577.		
/K.C./		Morice, et al. (1993) <i>J. Biological Chemistry</i> , Vol 268 (5) pp. 3734-3738.		
/K.C./		Poon, M., Badimon, J. & Fuster, V. (2002) <i>Lancet</i> 359, 619-622.		
/K.C./		Castedo, et al., (2002) <i>EMBO Journal</i> , 21 (15) pp. 4070-4080.		
/K.C./		Reeves J et al., (2002) <i>PNAS</i> 99: 16249-16254.		
/K.C./		Rizzardi, G., Harari, A., Capiluppi, B., Tambussi, G., Ellefsen, K., C'uffreda, D., Champagne, P., Bart, P., Chave, J., Lazzarin, A. & Pantaleo, G. (2002) <i>Clin. Invest.</i> 109, 681-688.		
/K.C./		Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) <i>Nat. Med.</i> 8, 128-135.		
/K.C./		Heredia, A.; Amoroso, A.; Davis, C.; Le, N.; Readon, E.; Klingebiel, E.; Gallo, R.C.; and Redfield R.R. (2003) <i>Proc. Natl. Acad. Sci. USA</i> , 100 (18) 10411-10416.		
/K.C./		Heredia, A., Davis, C., Amoroso, A., Dominique, J., Le, N., Klingebiel, E., Reardon, E., Zella, D. & Redfield, R. (2003) <i>Proc. Natl. Acad. Sci. USA</i> 100, 4179-4184.		
/K.C./		Heredia, A. et al, <i>Journal of Human Virology</i> 3(5): 248 (Sept-Oct 2000)		
/K.C./		Kahan, B. & Camardo, J. (2001) <i>Transplantation</i> 72, 1181-1193.		
/K.C./		Kinter, A., Poli, G., Fox, L., Hardy, E. & Fauci, A. (1995) <i>J. Immunol.</i> 154, 2448-2459.		
/K.C./		Lane, B., Markovitz, D., Woodford, N., Rochford, R., Strieter, R. & Coffey, M. (1999) <i>J. Immunol.</i> 163, 3653-3661.		
/K.C./		Terada N, et al., (1993) <i>J of Cellular Phys.</i> , 154 pp 7-15.		
/K.C./		Ullman, K., Northrop, J., Verweij, C. & Crabtree, G. (1990) <i>Annu. Rev. Immunol.</i> 8, 421-452.		
/K.C./		Ward, S., Bacon, K. & Westick, J. (1998) <i>Immunity</i> 9, 1-11.		
/K.C./		Weissman, D., Dybul, M., Daucher, M., Davey, R., Walker, R. & Kovacs, J. (2000) <i>J. Infect. Dis.</i> 181, 933-938.		
/K.C./		Willey, R., Smith, D., Lasky, L., Theodore, T., Earl, P., Moss, B., Capon, D. & Martin, M. (1988) <i>J. Virol.</i> 62, 139-147.		
/K.C./		Zella, D., Riva, A., Weichold, F., Reitz, M. & Gerna, G. (1998) <i>Immunol. Lett.</i> 62, 45-49.		
/K.C./		Roy, J., Sébastien, J., Fortin, J. & Tremblay, M. (2002) <i>Antimicrob. Agents Chemother.</i> 46, 3447-3455.		
/K.C./		Sehgal, S.-N. (1998) <i>Clin. Biochem.</i> 31, 335-340.		
/K.C./		Simmons, G., Clapham, P., Picard, L., Offord, R. E., Rosenkilde, M. M., Schwartz, T. W., Buser, R., Wells, T. N. & Proudfoot, A. E. (1997) <i>Science</i> 276, 276-279.		
/K.C./		Spina, C., Guatelli, J. & Richman, D. (1995) <i>J. Virol.</i> 69, 2977-2988.		
EXAMINER			DATE CONSIDERED	
/Kendra Carter/			05/06/2009	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.				